You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Leveraging platelet signal transduction for personalized antiplatelet therapy

    SBC: PlateletDiagnostics, LLC            Topic: NHLBI

    Project Summary/Abstract Platelet-mediated thrombosis causes both coronary arterial disease (CAD) and stroke, the first and fifth most common causes of mortality in the US. Antiplatelet agents, typically aspirin and/or clopidogrel, significantly improve survival in patients with CAD or stroke and have remained a mainstay of treatment for more than two decades. Yet despite the consensus that platel ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  2. Development of novel, targeted small molecule inhibitors of DNA repair in high unmet need tumors-TNBC

    SBC: DNATWO, Inc.            Topic: NCI

    DNATWO, Inc. was founded out of Caltech to develop small molecule drugs targeting a new cancer target, DNA2, to treat triple-negative breast cancer (TNBC). We have spent decades unraveling the role of the DNA2 ATP-motor driven nuclease activity in relieving replication stress at the replication fork and carrying out repair at forks collapsed to double strand breaks (DSBs). Our scientific premise i ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  3. An automated system to differentiate Kawasaki disease from febrile illness with real life clinical datasets in New York City

    SBC: HBI SOLUTIONS INC.            Topic: 100

    ABSTRACT – Kawasaki disease (KD) is the most common cause of acquired heart disease in children. Treatment with intravenous immunoglobulin (IVIG) reduces the incidence of coronary aneurysms and risk of long-term cardiovascular complications. IVIG is recommended to be given within 10 days of illness; however only 4.7% receive the correct diagnosis at the first medical visit. Timely and accurately ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  4. Clinical Decision Support System to Optimize Neonatal Nutrition and Growth

    SBC: Medical Predictive Science Corporation            Topic: NICHD

    Project Summary/Abstract: Clinical Decision Support System to Optimize Neonatal Nutrition and Growth Nutrition, defined as energy, macronutrients (protein, fat, and carbohydrates), and micronutrients (e.g., electrolytes), is a critical feature of care for preterm infants in the neonatal intensive unit (NICU). Inadequate nutrition is associated with growth and neurodevelopmental impairment, and inc ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  5. Development and Evaluation of an Integrated Biomarker Capture System for Use in Remote Trials

    SBC: MOUNTAINPASS TECHNOLOGY LLC            Topic: NCATS

    ABSTRACT Remote trials are led and coordinated by a local investigative team, but are based remotely, typically in the participant’s home. Remote trials offer several advantages over traditional in-person trials including: 1) a wider participant pool, 2) reduced regulatory hurdles, and 3) reduced participant burden. Remote trials face one key methodological limitation: the need for biomarker col ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  6. Glycoengineering of CHO cells to express recombinant alpha-1 antitrypsin

    SBC: NEUIMMUNE BIOLOGICS, INC.            Topic: NHLBI

    ABSTRACTAlpha-1 antitrypsin (A1AT) is well-established as a biotherapeutic used for the treatment of alpha-1 antitrypsin deficiency, and shows promise for treating a variety of other diseases. However, A1AT augmentation therapy carries unnecessary risk since it relies upon the weekly transfusion of plasma-derived product, which presents supply chain and contaminant risks. This could be remedied wi ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  7. Targeting a non-opioid signaling pathway to reverse opioid-induced respiratory depression

    SBC: Olfa Thera, Inc.            Topic: NIDA

    Project Summary/AbstractThe opioid epidemic is a growing public health crisis with dramatic increase in overdose deaths caused by potent opioids like fentanyl. Currently, the standard treatment for opioid-induced respiratory depression is naloxone, a µ-opioid receptor antagonist. However, naloxone is less effective against potent synthetic opioids like fentanyl and induces withdrawal in chronic o ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  8. Injectable Ice Slurry Cooling Technology for Treatment of Postoperative Pain

    SBC: Brixton Biosciences, Inc.            Topic: NIAMS

    Project SummaryTotal knee arthroplasty (TKA) is one of the most commonly performed orthopedic surgeries to relieve joint pain in patients with end-stage osteoarthritis or rheumatic arthritis. In the United States, over 700,000 TKA procedures are performed each year. Most patients experience significant pain after TKA. To manage this pain, patients are commonly prescribed opioids, contributing to a ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  9. Highly-sensitive, rapid and low cost plasmonic assay platform for Lyme disease diagnosis

    SBC: CIENCIA INC            Topic: NIAID

    Project Summary/Abstract Lyme disease (LD) is the most common vector-borne illness in the United States and represents a considerable diagnostic challenge. 1-3 The current benchmark for LD diagnosis is the standard two-tiered test (STTT), although the modified two-tier test (MTTT) is rapidly becoming an acceptable alternative. 6 These assays are highly specific but have poor sensitivity, especiall ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  10. Shim System for Removing ICD Artifacts from Patient Cardiac MR Images

    SBC: MIRTECH INC            Topic: NHLBI

    Project Abstract1.4 million people in the US (2021) have implanted cardioverter-defibrillators (ICDs) of which ~50% will require an MRI scan in their lifetime. All ICDs generate large artifacts in MRI such as signal-voids in cardiac MR (cMR) images, which frequently occur in important pathological (infarcted) regions. Reliable diagnosis of ventricular tachycardia, premature ventricular contraction ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government